Cargando…
Discovery of a cooperative mode of inhibiting RIPK1 kinase
RIPK1, a death domain-containing kinase, has been recognized as an important therapeutic target for inhibiting apoptosis, necroptosis, and inflammation under pathological conditions. RIPK1 kinase inhibitors have been advanced into clinical studies for the treatment of various human diseases. One of...
Autores principales: | Meng, Huyan, Wu, Guowei, Zhao, Xinsuo, Wang, Anhui, Li, Dekang, Tong, Yilun, Jin, Taijie, Cao, Ye, Shan, Bing, Hu, Shichen, Li, Ying, Pan, Lifeng, Tian, Xiaoxu, Wu, Ping, Peng, Chao, Yuan, Junying, Li, Guohui, Tan, Li, Wang, Zhaoyin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169668/ https://www.ncbi.nlm.nih.gov/pubmed/34075030 http://dx.doi.org/10.1038/s41421-021-00278-x |
Ejemplares similares
-
SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation
por: Xu, Gang, et al.
Publicado: (2021) -
PP6 negatively modulates LUBAC-mediated M1-ubiquitination of RIPK1 and c-FLIP(L) to promote TNFα-mediated cell death
por: Wu, Guowei, et al.
Publicado: (2022) -
RIPK1-Associated Inborn Errors of Innate Immunity
por: Zhang, Jiahui, et al.
Publicado: (2021) -
Targeting RIPK1 kinase for modulating inflammation in human diseases
por: Li, Wanjin, et al.
Publicado: (2023) -
Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis
por: Zhang, Xixi, et al.
Publicado: (2019)